Skip to main content

Teleflex Incorporated (TFX)

New York Stock Exchange Healthcare Medical - Instruments & SuppliesView data quality →
42.0Fair

ValueMarkers Composite Index

Top 9%#40,552 of 44,707
Undervalued

37% below intrinsic value ($166)

UndervaluedFair ValueOvervalued
Piotroski
4/9
Neutral
Beneish
-2.79
Low Risk
Altman
1.98
Grey Zone
DCF Value
$166
Undervalued
ROIC
4.3%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Teleflex Incorporated (TFX) — VMCI valuation read

TFX screens at VMCI 42/100, a 8-point gap below the Healthcare sector median (50). For a mid-cap Teleflex Incorporated share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

TFX has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: TFX trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -1.8x leaves covenant headroom, which sets the rate-cycle exposure for Teleflex Incorporated.

TFX rose 0.9% over the trailing 7 days, with a -4.0% read on a 30-day basis.

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

CEO: Stuart A. Randle14,100 employeesUSwww.teleflex.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in TFX’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.